Straits Times Index
3,303.19 +10.26 (+0.31%) S&P 500
5,152.60 +24.81 (+0.48%) Dow
38,696.15 +20.47 (+0.05%) Nasdaq
16,244.21 +87.88 (+0.54%) Bitcoin USD
63,475.46 -939.56 (-1.46%) CMC Crypto 200
1,372.07 +59.44 (+4.53%)
BCRX Sep 2024 7.000 call
| Previous close | 0.3000 |
| Open | 0.3500 |
| Bid | 0.3000 |
| Ask | 0.4000 |
| Strike | 7.00 |
| Expiry date | 2024-09-20 |
| Day's range | 0.3500 - 0.3500 |
| Contract range | N/A |
| Volume | |
| Open interest | 510 |
GuruFocus.comBioCryst Pharmaceuticals Reports Strong Q1 2024 Results, Exceeding Analyst Revenue Forecasts
Significant Growth in ORLADEYO Sales and Strategic Pipeline Advancements Mark the Quarter
ZacksBioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Tops Revenue Estimates
BioCryst (BCRX) delivered earnings and revenue surprises of 26.09% and 8.37%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireBioCryst Reports First Quarter 2024 Financial Results and Provides Business Update
—Q1 2024 ORLADEYO net revenue grows 30 percent y-o-y to $88.9 million— —Full-year 2024 ORLADEYO revenue guidance adjusted to $390-$400 million (top end of prior guidance range) — —Pipeline programs, including BCX17725 for Netherton syndrome and avoralstat for DME, advancing on schedule into clinical trials— RESEARCH TRIANGLE PARK, N.C., May 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the first quarter ended March 31, 2024, and pr
